Gilead Sciences Secures CHMP Support for Trodelvy Plus KEYTRUDA
FOSTER CITY, Calif., July 24, 2026 Gilead Sciences announced that the European Medicines Agency’s Committee for Medicinal Products for...
Trodelvy
Advertisement
Gilead Sciences Wins FDA Approval for Trodelvy in First-Line mTNBC
FOSTER CITY, Calif., June 24, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Merck and Gilead End KEYNOTE-D46 Study Update
RAHWAY, N.J. and FOSTER CITY, Calif., June 8, 2026 Merck (NYSE: MRK) and Gilead Sciences (Nasdaq: GILD) announced the...
Gilead’s Trodelvy Wins CHMP Support in 1L TNBC
FOSTER CITY, Calif., May 25, 2026 Gilead Sciences announced that the European Medicines Agency’s Committee for Medicinal Products for...
Marengo Reports Phase 2 Breast Cancer Data at AACR
CAMBRIDGE, Mass., April 17, 2026 Marengo Therapeutics, Inc. announced late-breaking Phase 2 clinical results for its investigational immunotherapy invikafusp...
Advertisements
IDEAYA Biosciences Enrolls First Patient in Phase 1/2 Combination Trial of IDE397 and Trodelvy® in MTAP-Deletion NSCLC
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company, announced the enrollment of the first patient in its...
Advertisement
